HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

beractant (Survanta)

a bovine lung extract that contains mostly phospholipids; modified by the addition of dipalmitoylphosphatidylcholine, palmitic acid, and tripalmitin
Also Known As:
Survanta; surfactant-TA
Networked: 144 relevant articles (23 outcomes, 38 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Dilmen, Ugur: 4 articles (04/2016 - 02/2012)
2. Dizdar, Evrim Alyamaç: 2 articles (01/2021 - 12/2013)
3. Sekar, Krishnamurthy: 2 articles (03/2019 - 04/2004)
4. Erdeve, Omer: 2 articles (04/2016 - 02/2012)
5. Uras, Nurdan: 2 articles (04/2016 - 02/2012)
6. Dizdar, Evrim Alyamac: 2 articles (06/2014 - 02/2012)
7. Oguz, Serife Suna: 2 articles (12/2013 - 02/2012)
8. Sari, Fatma Nur: 2 articles (12/2013 - 02/2012)
9. Waring, Alan J: 2 articles (02/2012 - 12/2002)
10. Allen, R: 2 articles (10/2010 - 10/2010)

Related Diseases

1. Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
2. Newborn Respiratory Distress Syndrome
3. Lung Diseases (Lung Disease)
4. Bronchopulmonary Dysplasia
5. Lung Injury
08/01/2005 - "After lung injury by instillation of meconium, they were treated with Survanta, Survanta with HA, or control mixtures. "
08/01/2000 - "The greatest improvement in both oxygenation (178%) and compliance (42%) occurred in animals with lung injury that were treated with Survanta and PEG (versus untreated control animals; p < 0.01), whereas little improvement was found after treatment with Survanta alone. "
10/01/2006 - "Based on morphology, histopathology, white blood cell count, percentage of PMNs, and protein concentration in bronchoalveolar lavage fluid, our data showed KL(4)-surfactant, unlike vehicle or beractant, blocked neutrophil influx into alveoli and suppressed lung injury. "
10/01/2006 - "For the hyperoxic injury model, mice exposed to 80% O(2) for 6 days received an intranasal bolus of vehicle, beractant, or KL(4)-surfactant on days 3, 4, 5, and 6 of the exposure, and lungs were evaluated on day 7. Mice in the LPS-induced lung injury model received an intratracheal bolus of LPS followed by an intranasal bolus of KL(4)-surfactant or control at 1, 3, and 19 hr post-LPS challenge, and lungs were evaluated after 24 hr. To explore the mechanisms of protection, in vitro assays were performed with human and murine endothelial cell monolayers, and polymorphonuclear leukocyte (PMN) transmigration in the presence or absence of KL(4)-surfactant or lipid controls was evaluated. "
11/01/2005 - "We treated rats with lavage lung injury with a commercial lung surfactant extract derived from bovine lung (Survanta) with or without addition of PEG. "

Related Drugs and Biologics

1. Surface-Active Agents (Surfactants)
2. poractant alfa (Curosurf)
3. beractant (Survanta)
4. tyloxapol drug combination hexadecanol dipalmitoylphosphatidylcholine (Exosurf Neonatal)
5. calfactant (Infasurf)
6. bovine surfactant preparation SF-RI 1
7. colfosceril palmitate
8. Oxygen (Dioxygen)
9. Suspensions
10. Protein C

Related Therapies and Procedures

1. Artificial Respiration (Mechanical Ventilation)
2. Aftercare (After-Treatment)
3. Therapeutics
4. Extracorporeal Membrane Oxygenation
5. Mechanical Ventilators (Ventilator)